Personalising the Fight against Triple Negative Breast Cancer

Research output: Contribution to journalReview article

3541 Downloads (Pure)

Abstract

Triple Negative Breast Cancer (TNBC) is a highly heterogeneous disease. Lacking hormone receptors, ER and PR, as well as HER2 amplification, these cancers cannot be treated with more modern, targeted therapies such as tamoxifen or trastuzumab. Thus, the current standard of care for these patients is cytotoxic chemotherapy with varied clinical response. However, all patients experience unwanted and debilitating side effects regardless of response. Therefore, TNBC represents a significant unmet clinical need and finding more targeted and effective treatment approaches for this aggressive disease is an area of active research. The success of such agents has been hindered by the heterogeneity of the disease, with many new drugs only showing promising results in small populations. In order for targeted treatments to succeed, predictive biomarkers must be developed which can stratify patients and drive treatment choices. This review looks at the most promising areas of research regarding targeted therapy in TNBC as well as associated biomarkers that can be used to guide treatment.
Original languageEnglish
Number of pages12
JournalJournal of Breast Cancer Research and Advancements
Volume1
Issue number1
DOIs
Publication statusPublished - 12 Jul 2018

Fingerprint

Triple Negative Breast Neoplasms
Therapeutics
Biomarkers
Tamoxifen
Standard of Care
Research
Hormones
Drug Therapy
Pharmaceutical Preparations
Population

Cite this

@article{db266bb00ccd42ad908b8f1bc9f9d516,
title = "Personalising the Fight against Triple Negative Breast Cancer",
abstract = "Triple Negative Breast Cancer (TNBC) is a highly heterogeneous disease. Lacking hormone receptors, ER and PR, as well as HER2 amplification, these cancers cannot be treated with more modern, targeted therapies such as tamoxifen or trastuzumab. Thus, the current standard of care for these patients is cytotoxic chemotherapy with varied clinical response. However, all patients experience unwanted and debilitating side effects regardless of response. Therefore, TNBC represents a significant unmet clinical need and finding more targeted and effective treatment approaches for this aggressive disease is an area of active research. The success of such agents has been hindered by the heterogeneity of the disease, with many new drugs only showing promising results in small populations. In order for targeted treatments to succeed, predictive biomarkers must be developed which can stratify patients and drive treatment choices. This review looks at the most promising areas of research regarding targeted therapy in TNBC as well as associated biomarkers that can be used to guide treatment.",
author = "Ahmed Elkashif and McCarthy, {Helen O} and Buckley, {Niamh E}",
year = "2018",
month = "7",
day = "12",
doi = "10.16966/2638-3527.106",
language = "English",
volume = "1",
journal = "Journal of Breast Cancer Research and Advancements",
number = "1",

}

TY - JOUR

T1 - Personalising the Fight against Triple Negative Breast Cancer

AU - Elkashif, Ahmed

AU - McCarthy, Helen O

AU - Buckley, Niamh E

PY - 2018/7/12

Y1 - 2018/7/12

N2 - Triple Negative Breast Cancer (TNBC) is a highly heterogeneous disease. Lacking hormone receptors, ER and PR, as well as HER2 amplification, these cancers cannot be treated with more modern, targeted therapies such as tamoxifen or trastuzumab. Thus, the current standard of care for these patients is cytotoxic chemotherapy with varied clinical response. However, all patients experience unwanted and debilitating side effects regardless of response. Therefore, TNBC represents a significant unmet clinical need and finding more targeted and effective treatment approaches for this aggressive disease is an area of active research. The success of such agents has been hindered by the heterogeneity of the disease, with many new drugs only showing promising results in small populations. In order for targeted treatments to succeed, predictive biomarkers must be developed which can stratify patients and drive treatment choices. This review looks at the most promising areas of research regarding targeted therapy in TNBC as well as associated biomarkers that can be used to guide treatment.

AB - Triple Negative Breast Cancer (TNBC) is a highly heterogeneous disease. Lacking hormone receptors, ER and PR, as well as HER2 amplification, these cancers cannot be treated with more modern, targeted therapies such as tamoxifen or trastuzumab. Thus, the current standard of care for these patients is cytotoxic chemotherapy with varied clinical response. However, all patients experience unwanted and debilitating side effects regardless of response. Therefore, TNBC represents a significant unmet clinical need and finding more targeted and effective treatment approaches for this aggressive disease is an area of active research. The success of such agents has been hindered by the heterogeneity of the disease, with many new drugs only showing promising results in small populations. In order for targeted treatments to succeed, predictive biomarkers must be developed which can stratify patients and drive treatment choices. This review looks at the most promising areas of research regarding targeted therapy in TNBC as well as associated biomarkers that can be used to guide treatment.

U2 - 10.16966/2638-3527.106

DO - 10.16966/2638-3527.106

M3 - Review article

VL - 1

JO - Journal of Breast Cancer Research and Advancements

JF - Journal of Breast Cancer Research and Advancements

IS - 1

ER -